GlassScriptPhysician profile
Andrea Howell
NPI 1225579741
$3,646.21
in general payments reported to CMS, 2019-2025
33 companies · $20.40 in 2025
The $20.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $807 · 2023: $869 · 2024: $1,024 · 2025: $20.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.61 | 2021-2024 | Xifaxan, Trulance |
| Abbvie INC. | $375.95 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $319.89 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $275.21 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $252.65 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $248.49 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.95 | 2021-2024 | Synjardy, Tradjenta, Jardiance |
| Corium, LLC | $167.76 | 2023-2024 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.50 | 2022-2024 | Caplyta |
| Antares Pharma, INC. | $161.48 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Esperion Therapeutics, INC. | $97.89 | 2021-2024 | Nexletol |
| Novo Nordisk INC | $94.45 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $92.10 | 2022-2024 | |
| Amgen INC. | $81.13 | 2021-2024 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $75.05 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $68.67 | 2022-2024 | Rexulti |
| Abbott Laboratories | $52.27 | 2022-2023 | Proclaim, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $47.98 | 2021 | |
| Dexcom, INC. | $44.54 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $43.61 | 2023-2024 | |
| Scynexis, INC. | $38.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.43 | 2024 | |
| Eisai INC. | $33.54 | 2021-2022 | |
| Dynavax Technologies Corporation | $32.21 | 2023 | Heplisav-B |
| Adlon Therapeutics L.P. | $32.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.07 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $23.55 | 2024 | |
| Astellas Pharma US INC | $17.59 | 2024 | Veozah |
| Halozyme INC | $16.01 | 2023 | |
| Abiomed | $15.87 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $14.50 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.04 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.